Navigation Links
ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
Date:2/14/2011

CHICAGO, Feb. 14, 2011 /PRNewswire/ -- Zoledronic acid (sold by Novartis as Zometa, Aclasta, and Reclast) is used to treat Osteoporosis, Tumor Metastasis, and Paget's Disease with sales of $2 billion a year.(1)  It is associated with side effects such as post-dose syndrome and osteonecrosis of the jaw.  A new patented method from Dr. Ketan Desai enables the administration of Zoledronic acid in combination with another drug that relieves the side effects.

(Logo:  http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

This patented method will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City. Key Characteristics of MethodThe patents disclose the following:


  • Method enables administration of zoledronic acid in a novel combination.
  • Method results in decreased side effects.
  • Can be administered though different methods: oral supply, inhalation, muscle injection, or veindrip.
  • Market OverviewThese patents may be of interest in the following areas:


  • The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expect to reach $32.8 billion in 2013.(2)
  • These patents would be of interest to: pharmaceutical companies, drug manufacturers, healthcare service providers, and biomedical research.
  • To learn more about the assets available for sale in this portfolio: Contact Dean Becker of ICAP Ocean Tomo at Dean.Becker@us.icap.comAbout ICAP Ocean Tomo LLCICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.

    About ICAPICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.

    (1) http://www.thepharmaletter.com/file/100554/novartis-zometa-fails-to-meet-ph-iii-primary-endpoint-in-early-breast-cancer-stalling-this-indication-but-afinitor-looks-good.html

    (2) http://www.bccresearch.com/report/HLC026C.html


    '/>"/>

    SOURCE ICAP Ocean Tomo
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
    2. ICAP Ocean Tomo to Auction 7 Exclusive Licenses from Lawrence Livermore National Laboratory at Fall Auction November 11th in Napa, California
    3. Skin Lesion Identification System to Auction on November 11th at ICAP Ocean Tomos Fall 2010 Live IP Auction
    4. ICAP Ocean Tomo Offers for Sale IP Portfolio of Active Implants for Electromagnetic Bone and Tissue Regeneration in Orthopedics, Trauma, and Wound Care
    5. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
    6. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
    7. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
    8. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
    9. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
    10. Dynatronics Announces Fiscal Second Quarter Results
    11. K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
    (Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
    (Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
    (Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
    (Date:6/24/2016)... ... 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... service members that have been wounded in battle and their families. Venture Construction Group ...
    Breaking Medicine News(10 mins):